Consistent with previous findings targeting VEGF-A [30], we observed a decrease in vessel number and diameter using either bevacizumab or 2H10 as a monotherapy, accompanied by reduced proliferation in tumors, consistent with effects on tumor cells expressing VEGFR1. The gene discussed is VEGFA; the disease is neoplasm.